跳至主要内容
临床试验/NCT00007943
NCT00007943已完成2 期

A Phase II Study Of Twenty-Four Hour Infusion Gemcitabine For Advanced Colorectal Cancer

Wake Forest University Health Sciences2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2000年9月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
15
试验地点
2

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have advanced colorectal cancer.

详细描述

OBJECTIVES:

  • Determine the response rate in patients with advanced colorectal cancer treated with gemcitabine.
  • Determine the toxic effects of this drug in these patients.
  • Determine the progression-free survival of patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive gemcitabine IV continuously over 24 hours on days 1, 8, and 15. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验